by Miriam Rauschert | Feb 19, 2021 | Uncategorized
The report includes comparisons of success rates across indications and modalities, regulatory factors, and predictive factors driving successes and failures in drug development. This new data will help shape risk profiles and valuation metrics across investment and...
by Miriam Rauschert | Dec 2, 2020 | Uncategorized
Partnership will help inform key decisions with new drug-level probability of approval scores powered by QLS and incorporated into Informa Pharma Intelligence’s Biomedtracker LONDON, Dec. 02, 2020 (GLOBE NEWSWIRE) — Informa Pharma Intelligence, the global...
Recent Comments